AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19170708 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH 75 IU
Number of subjects: 0
Study 19170708 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH 225 IU
Number of subjects: 0
Study 19170708 — intervention group
Group type: EXPERIMENTAL
Intervention: rhCG 250 microg
Number of subjects: 0
Study 19170708 — intervention group
Group type: EXPERIMENTAL
Intervention: rhCG 750 microg
Number of subjects: 0
Study 19170708 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) suppression
Number of subjects: 0
Study 16303817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-intensity ultrasound therapy (LIUS)
Number of subjects: 55
Study 16303817 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 55
Study 15973019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium tuberculosis H37Ra excretory‐secretory antigen (ES‐31) and affinity purified goat anti ES‐31 antibodies
Number of subjects: 230
Study 15973019 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of circulating free and immune complexed antigen (CIC‐Ag)
Number of subjects: 230
Study 11960413 — intervention group
Group type: EXPERIMENTAL
Intervention: Talent stent-grafts
Number of subjects: 16
Study 11960413 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore-TAG stent-graft
Number of subjects: 16
Study 9865221 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0
Study 9865221 — intervention group
Group type: COMPARATOR
Intervention: Standard Case Management (SCM)
Number of subjects: 0
Study 7622763 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol/CFC-free (100, 200, and 300 micrograms)
Number of subjects: 26
Study 7622763 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol/CFC (100 and 200 micrograms)
Number of subjects: 26
Study 7622763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2467781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent informed consent process utilizing audiovisual and written material as well as behavioral practice
Number of subjects: 0
Study 51860 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterirritation (10-sec immersion of fingers into a 2 degrees C water bath)
Number of subjects: 18
Study 51860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control procedure)
Number of subjects: 18
Study 30808774 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 4547
Study 30808774 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 4547
Study 28429539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intrauterine filling pressures (30, 40, and 50 mmHg)
Number of subjects: 175
Study 28429539 — intervention group
Group type: COMPARATOR
Intervention: Higher intrauterine filling pressures (70, 80, and 100 mmHg)
Number of subjects: 175
Study 26339938 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular ultrasound
Number of subjects: 382
Study 26339938 — intervention group
Group type: COMPARATOR
Intervention: Standard landmark method
Number of subjects: 382
Study 23323659 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed Self-Regulated Learning (DSRL)
Number of subjects: 37
Study 23323659 — intervention group
Group type: COMPARATOR
Intervention: Self-Regulated Learning (SRL)
Number of subjects: 37
Study 21646251 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC's 'Heads Up' toolkit
Number of subjects: 414
Study 21646251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no toolkit)
Number of subjects: 414
Study 18796184 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg
Number of subjects: 102
Study 18796184 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 102
Study 18796184 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 102
Study 18796184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18796184 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (all doses)
Number of subjects: 102
Study 18796184 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg and 50 mg)
Number of subjects: 102
Study 16953990 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily oral hygiene care with 0.12% chlorhexidine gluconate
Number of subjects: 5
Study 16953990 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care 6 times per day with soft foam swab and half strength hydrogen peroxide
Number of subjects: 5
Study 15206694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclosporin A therapy
Number of subjects: 0
Study 15206694 — intervention group
Group type: COMPARATOR
Intervention: UVAB phototherapy
Number of subjects: 0
Study 11316172 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 2 mg + Terlipressin 2 mg
Number of subjects: 24
Study 11316172 — intervention group
Group type: COMPARATOR
Intervention: Terlipressin 2 mg
Number of subjects: 24
Study 11316172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9141937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP plus oxygen
Number of subjects: 30
Study 9141937 — intervention group
Group type: COMPARATOR
Intervention: Oxygen by face mask
Number of subjects: 30
Study 7609516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg
Number of subjects: 17
Study 7609516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 6 mg
Number of subjects: 17
Study 7609516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 8 mg
Number of subjects: 17
Study 7609516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (all doses)
Number of subjects: 17
Study 3129313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) pulsatile LH‐RH therapy (50 to 100 ng/kg body weight/90 to 120 minutes)
Number of subjects: 5
Study 3129313 — intervention group
Group type: COMPARATOR
Intervention: Naloxone administration (2 mg IV bolus plus 4 mg infusion lasting 120 minutes)
Number of subjects: 5
Study 29662493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum bv. infantis CCUG 52486 combined with gluco-oligosaccharide (B. longum + Gl-OS)
Number of subjects: 0
Study 29662493 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0
Study 29662493 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28038841 — intervention group
Group type: EXPERIMENTAL
Intervention: OKd (discontinued ortho-k lens wear for 7 months, then resumed for 7 months)
Number of subjects: 44
Study 28038841 — intervention group
Group type: EXPERIMENTAL
Intervention: OKc (continued ortho-k lens wear throughout the study)
Number of subjects: 44
Study 28038841 — intervention group
Group type: COMPARATOR
Intervention: Control (continued wearing spectacles)
Number of subjects: 44
Study 24297383 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte-methotrexate-polyglutamate (MTX-PG) concentrations
Number of subjects: 387
Study 24297383 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-PG1, MTX-PG2, MTX-PG3, total MTX-PG
Number of subjects: 387
Study 24297383 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-PG2, MTX-PG3, MTX-PG4, total MTX-PG
Number of subjects: 387
Study 23948835 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cross-friction treatment on the thoraco-lumbar Erector spinae and gluteals, 30 minutes, two sessions per week
Number of subjects: 100
Study 23948835 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 20980977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein intake (0.58 g/kg per day)
Number of subjects: 741
Study 20980977 — intervention group
Group type: COMPARATOR
Intervention: Usual protein intake (1.3 g/kg per day)
Number of subjects: 741
Study 20980977 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein intake (0.28 g/kg per day)
Number of subjects: 741
Study 20980977 — intervention group
Group type: COMPARATOR
Intervention: Low protein intake (0.58 g/kg per day) in study B
Number of subjects: 741
Study 18093273 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol biopsies at 1 and 3 months
Number of subjects: 102
Study 18093273 — intervention group
Group type: COMPARATOR
Intervention: Control group (indicated biopsies only)
Number of subjects: 102
Study 16441798 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Rhino Riemann pack
Number of subjects: 45
Study 16441798 — intervention group
Group type: COMPARATOR
Intervention: Telfa pack
Number of subjects: 45
Study 12895183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox gel 0.77% applied twice daily for 28 days
Number of subjects: 178
Study 12895183 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied twice daily for 28 days
Number of subjects: 178
Study 12895183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox gel 0.77%
Number of subjects: 178
Study 12895183 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 178
Study 10618300 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair (n=34)
Number of subjects: 84
Study 10618300 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (n=35)
Number of subjects: 84
Study 10618300 — intervention group
Group type: COMPARATOR
Intervention: VSD patients
Number of subjects: 84
Study 8704066 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 8704066 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 1315644 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions of 30 min cycling at 70% of maximal capacity for 4 weeks)
Number of subjects: 10
Study 1315644 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 10
Study 3910771 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily (group CD)
Number of subjects: 34
Study 3910771 — intervention group
Group type: COMPARATOR
Intervention: Previous regimen (beta-blockers and diuretics) (group BD)
Number of subjects: 34
Study 31155159 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom lectures
Number of subjects: 131
Study 31155159 — intervention group
Group type: COMPARATOR
Intervention: Simulation course
Number of subjects: 131
Study 28807519 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity social concerns
Number of subjects: 298
Study 28807519 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity cognitive concerns
Number of subjects: 298
Study 28807519 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory intolerance of uncertainty
Number of subjects: 298
Study 28807519 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect (NA)
Number of subjects: 298
Study 26656672 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment (four 30-min behavioral counseling sessions)
Number of subjects: 131
Study 26656672 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 131
Study 23572043 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal debridement technique
Number of subjects: 47
Study 23572043 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 47
Study 22053921 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous event schedule (temporally regular)
Number of subjects: 0
Study 22053921 — intervention group
Group type: COMPARATOR
Intervention: Asynchronous event schedule (temporally irregular)
Number of subjects: 0
Study 20439197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab/docetaxel/gemcitabine
Number of subjects: 69
Study 18616366 — intervention group
Group type: EXPERIMENTAL
Intervention: Midface advancement by osteotomy
Number of subjects: 15
Study 18616366 — intervention group
Group type: COMPARATOR
Intervention: Midface advancement by distraction
Number of subjects: 15
Study 16115108 — intervention group
Group type: EXPERIMENTAL
Intervention: Malassezia colonisation
Number of subjects: 245
Study 16115108 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida colonisation
Number of subjects: 245
Study 16115108 — intervention group
Group type: EXPERIMENTAL
Intervention: Malassezia and Candida co-colonisation
Number of subjects: 245
Study 16115108 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces colonisation
Number of subjects: 245
Study 16115108 — intervention group
Group type: EXPERIMENTAL
Intervention: Malassezia furfur
Number of subjects: 245
Study 16115108 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida albicans
Number of subjects: 245
Study 11834133 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of tibolone, taken daily for 12 months
Number of subjects: 85
Study 11834133 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills, taken daily for 12 months
Number of subjects: 85
Study 11300380 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone 0.2 microg x kg(‐1) x min(‐1)
Number of subjects: 23
Study 11300380 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone 0.1 microg x kg(‐1) x min(‐1)
Number of subjects: 23
Study 11300380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9002565 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician visual assessment
Number of subjects: 3949
Study 9002565 — intervention group
Group type: COMPARATOR
Intervention: Not seen by EP
Number of subjects: 3949
Study 9002565 — intervention group
Group type: COMPARATOR
Intervention: All RN triage
Number of subjects: 3949
Study 9002565 — intervention group
Group type: EXPERIMENTAL
Intervention: Seen by EP
Number of subjects: 3949
Study 9002565 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage categories visualized by EP
Number of subjects: 3949
Study 9002565 — intervention group
Group type: COMPARATOR
Intervention: Triage categories not visualized by EP
Number of subjects: 3949
Study 8510513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 10% (0.3 g triglyceride [TG]/kg/h for 6 hours)
Number of subjects: 10
Study 8510513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidem (0.1 g/kg/h for 6 hours)
Number of subjects: 10
Study 8510513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both emulsions infused in random order (0.1 g/kg/h for 6 hours)
Number of subjects: 10
Study 3525430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 384
Study 3525430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 384
Study 29665518 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT + DIR
Number of subjects: 42
Study 29665518 — intervention group
Group type: COMPARATOR
Intervention: DIR-alone
Number of subjects: 42
Study 28446441 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine (3.75 μg HA)
Number of subjects: 261
Study 28446441 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine (15 μg HA)
Number of subjects: 261
Study 28446441 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted vaccine (3.75 μg HA)
Number of subjects: 261
Study 26521019 — intervention group
Group type: COMPARATOR
Intervention: Lurasidone 20 mg/day
Number of subjects: 0
Study 26521019 — intervention group
Group type: COMPARATOR
Intervention: Lurasidone 80 mg/day
Number of subjects: 0
Study 26521019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/day
Number of subjects: 0
Study 26521019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23578605 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (10, 20, 40, or 80 μg/d)
Number of subjects: 44
Study 23578605 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 (40 and 80 μg/d)
Number of subjects: 44
Study 23578605 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650
Number of subjects: 44
Study 21178082 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg/d from wk 20 of gestation through delivery)
Number of subjects: 739
Study 21178082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study 21178082 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 739
Study 18280336 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 62
Study 18280336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16547162 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic categorization strategy analysis
Number of subjects: 0
Study 12488300 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone (2,200 mg/m² biweekly)
Number of subjects: 83
Study 12488300 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus capecitabine (2,200 mg/m² gemcitabine biweekly + 2,500 mg/m² capecitabine days 1-7)
Number of subjects: 83
Study 12488300 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Number of subjects: 83
Study 12488300 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus capecitabine
Number of subjects: 83
Study 11082090 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 100
Study 11082090 — intervention group
Group type: COMPARATOR
Intervention: Hospital care
Number of subjects: 100
Study 9367703 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (2 mg)
Number of subjects: 196
Study 9367703 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (4 mg)
Number of subjects: 196
Study 9367703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 1552746 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX, 1 g/m2)
Number of subjects: 427
Study 1552746 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation and intrathecal MTX
Number of subjects: 427
Study 1552746 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide/cytarabine and delayed cranial irradiation
Number of subjects: 427
Study 1552746 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 427
Study 1552746 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful remission retrieval therapy
Number of subjects: 427
Study 1552746 — intervention group
Group type: EXPERIMENTAL
Intervention: Total long-term survivors
Number of subjects: 427
Study 31172107 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-Ketamine (PK)
Number of subjects: 110
Study 31172107 — intervention group
Group type: COMPARATOR
Intervention: Propofol-Fentanyl (PF)
Number of subjects: 110
Study 27180101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary implant
Number of subjects: 91
Study 27180101 — intervention group
Group type: COMPARATOR
Intervention: Kirschner wire
Number of subjects: 91
Study 26391465 — intervention group
Group type: COMPARATOR
Intervention: Monthly dosing of intravitreal 0.5 mg ranibizumab
Number of subjects: 60
Study 26391465 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-and-extend (TREX) management strategy
Number of subjects: 60
Study 23753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 607
Study 23753091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study 21961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss
Number of subjects: 439
Study 21961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Number of subjects: 439
Study 21961463 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 439
Study 21961463 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 439
Study 19999191 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Obstetric Care (EmOC) services
Number of subjects: 170
Study 19999191 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors limiting access to EmOC services
Number of subjects: 170
Study 19999191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural norms
Number of subjects: 170
Study 19999191 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facilities' working hours
Number of subjects: 170
Study 19999191 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase skilled female workers
Number of subjects: 170
Study 16627214 — intervention group
Group type: EXPERIMENTAL
Intervention: Antox (combined antioxidant preparation containing selenium, betacarotene, L-methionine, vitamins C and E)
Number of subjects: 36
Study 16627214 — intervention group
Group type: EXPERIMENTAL
Intervention: Antox
Number of subjects: 36
Study 16627214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14693733 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IGF‐I levels before biopsy
Number of subjects: 1031
Study 14693733 — intervention group
Group type: EXPERIMENTAL
Intervention: GST‐T1 variant alleles
Number of subjects: 1031
Study 14693733 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I variant alleles
Number of subjects: 1031
Study 14693733 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, ethnicity, total PSA, and DRE result
Number of subjects: 1031
Study 14693733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine of 11 candidate genes
Number of subjects: 1031
Study 14693733 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I levels
Number of subjects: 1031
Study 11014092 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc injection (20‐40 MBq)
Number of subjects: 40
Study 11014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue dye injection
Number of subjects: 40
Study 11014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 99mTc and blue dye
Number of subjects: 40
Study 11014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value
Number of subjects: 40
Study 11014092 — intervention group
Group type: EXPERIMENTAL
Intervention: SN mapping
Number of subjects: 40
Study 11014092 — intervention group
Group type: EXPERIMENTAL
Intervention: Micrometastasis
Number of subjects: 40
Study 11014092 — intervention group
Group type: EXPERIMENTAL
Intervention: SN being the only nodal metastasis
Number of subjects: 40
Study 8783666 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine with 4‐hydroperoxycyclophosphamide (4‐HC)
Number of subjects: 0
Study 8783666 — intervention group
Group type: COMPARATOR
Intervention: 4‐hydroperoxycyclophosphamide (4‐HC) without amifostine
Number of subjects: 0